CoQ10 and D-ribose in Patients With Diastolic Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT03133793

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03133793
Other papers using this trial's data
  • Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction The American journal of cardiology, 2022-08-01 DOI, PubMed 35644694, PMC9576187 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03133793. Randomized; double masking; primary purpose treatment. Start 2018-02-05 (actual); primary completion 2021-03-12 (actual). Results posted on 2022-03-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Condition
Heart Failure, Diastolic
Intervention (Drug)
CoQ10
Intervention (Drug)
D-Ribose Oral Powder
Intervention (Other)
Placebo pills
Intervention (Other)
Placebo powder
Lead sponsor
University of Kansas Medical Center (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03133793
Content hash
d51b0de19a924722dcea81949a3e52e81033c5ac7621eaa25dff369387a09a10